GYRE THERAPEUTICS, INC.
Ticker: 1124105
values in millions
Revenue & Profit Trend
in millionsRevenueExpenditureNet Profit
Margin Trend
percentageOPM %NPM %
| Period | Q1 FY2026 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 | Q3 FY2024 | Q2 FY2024 | Q1 FY2024 | Q1 FY2022 |
|---|---|---|---|---|---|---|---|---|
| INCOME | ||||||||
| Revenue | 22.52-26.3% | 30.56+14.2% | 26.77+21.4% | 22.06-13.5% | 25.49+1.0% | 25.23-7.1% | 27.17+3339.2% | 0.79 |
| Total Income | 22.52-26.3% | 30.56+14.2% | 26.77+21.4% | 22.06-13.5% | 25.49+1.0% | 25.23-7.1% | 27.17+3339.2% | 0.79 |
| EXPENSES | ||||||||
| Expenditure | 31.87+34.8% | 23.64-3.9% | 24.60+24.3% | 19.79-6.9% | 21.26-3.2% | 21.96+15.0% | 19.10+23.2% | 15.50 |
| Tax | 0.62-63.3% | 1.69+156.1% | 0.66-26.7% | 0.90-15.9% | 1.07-28.7% | 1.50-41.2% | 2.55 | — |
| PROFIT | ||||||||
| PBT | -9.24-221.1% | 7.63+240.6% | 2.24-51.7% | 4.64+18.1% | 3.93-34.9% | 6.04-51.6% | 12.48 | — |
| Net Profit | -9.86-266.0% | 5.94+275.9% | 1.58-57.6% | 3.73+30.4% | 2.86-37.0% | 4.54-54.3% | 9.94+168.4% | -14.54 |
| KEY METRICS | ||||||||
| OPM % | -41.54%-64.20pp | 22.66%+14.55pp | 8.11%-2.20pp | 10.30%-6.30pp | 16.61%+3.68pp | 12.93%-16.77pp | 29.70%+129.70pp | -100.00% |
| NPM % | -43.78%-63.20pp | 19.42%+13.54pp | 5.89%-11.04pp | 16.93%+5.72pp | 11.21%-6.78pp | 17.99%-18.57pp | 36.56%+136.56pp | -100.00% |
| EPS | -0.10-350.0% | 0.04 | 0.00-100.0% | 0.03+200.0% | 0.01-75.0% | 0.04-55.6% | 0.09 | — |
Corporate Events
Board MeetingGYRE
202610Jun
Board Meeting
Results of the 2026 Annual Meeting of Stockholders, includin…
SEC Filing ↗ Board MeetingGYRE
20264May
Board Meeting
Acquisition of Cullgen Inc. closed; Dr. Ying Luo appointed P…
SEC Filing ↗